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Hepatitis C viruses (HCV) present in 110 Italian patients were characterized by genotype-specific PCRs.
Among the 65 cases of community-acquired hepatitis, HCV genotype IT was dominant (60%o), followed by
genotypes IV (15%),m (11%), and I (3%). Among the 45 hemophilia-associated cases, the distribution of the
four HCV genotypes was markedly different: genotype I was the most prevalent (61%), followed by genotypes
II (25%), m (4%), and IV (2%). Double infections were observed in eight patients. Two HCV remained
unclassified. For the 45 community-acquired cases from which a liver biopsy was available, genotype H was
associated with more severe liver damage than the other ypes.
Hepatitis C viruses (HCV) are the major etiologic agents
of posttransfusion and community-acquired or sporadic
non-A, non-B hepatitis. Since the viral genome was cloned a
few years ago (4), extensive use of molecular techniques has
led to a detailed characterization of its structure, even
though many aspects of the biology and epidemiology of the
virus remain elusive (5).
On the basis of differences in the nucleotide sequence of
the core gene, Okamoto et al. have grouped the HCV
detected in different patients into at least four genotypes,
which can be readily recognized by the use of genotype-
specific PCR (8). The limited epidemiological data available
indicate that the relative prevalences of such genotypes may
vary considerably in different regions of the world (2).
Genotype I appears to be predominant in the United States
(70%, also called American prototype), genotype II appears
to be predominant in Japan (77%, Japanese K1), while
genotypes III and IV (Japanese K2a and K2b, respectively)
show lower prevalences in Japan (16 and 5%, respectively)
and are rarely found in the United States and western
countries (10% for genotypes III and IV) (12). Other HCV
classifications have been proposed. For example, Simmonds
et al. identified six genotypes on the basis of the sequence
configuration in the 5'-untranslated region (3, 11); according
to this classification, genotypes I and II of Okamoto et al. are
grouped into type 1 (la and lb subtypes, respectively),
genotypes III and IV of Okamoto et al. are grouped into type
2 (2a and 2b subtypes, respectively). However, the classifi-
cation proposed by Okamoto et al. is still widely used.
Studies are now in progress to investigate whether HCV
genotypes differ in routes of transmission or result in differ-
ent clinical outcomes (1, 13). In this study, we have exam-
ined the distribution in 110 Italian patients of the four HCV
genotypes identified by Okamoto et al. These subjects had
previously been found to be viremic by a nested reverse
transcriptase PCR which recognizes most if not all HCV (6),
as it uses primers covering the conserved 5'-untranslated
region of the viral genome (Fig. 1, universal PCR). Sixty five
patients had community-acquired infections, while 45 were
hemophiliacs who had been extensively treated with com-
mercial coagulation factor concentrates in previous years.
The patients lived mainly in northern and central Italy and
were aged 15 to 84 years. After collection, the sera were
stored at -80°C until analyzed. According to a published
procedure (10), to minimize the risk of contamination, geno-
typing was performed directly on serum, since prior studies
had shown that RNA extraction could be omitted with no
apparent loss of sensitivity. Viral RNA was first reverse
transcribed and then amplified for 35 cycles (melting at 94°C
for 3 min in the first cycle and for 30 s in the following ones,
annealing at 45°C for 1 min, and extension at 72°C for 3 min)
with the first-step primers shown in Fig. 1 (genotype-specific
PCR). The product of such a reaction was then reamplified
for 24 cycles (the temperature and duration of each step were
as described above) with a mixture of genotype-specific,
second-step primers (Fig. 1). The amplified products were
finally analyzed by gel electrophoresis in 4% agarose and
UNIVERSAL PCR
2nd stop
ATGOCCTTAGTATGACTG - CGCCACCCAACACTACTCOGGCT
AACTACTGTCTTCACGCAGAA GATGCACGGTCTACGAGA C
S' UTRm E
186bp (nt -257 to -70)
289bp (nt -289 to -1)
E2/NSI
GENOTYPE-SPECIFIC PCR
l.t st-p
CGCGCGACTAGGAAGACTTC ATGTACCCCATGAGGTCGGC 272bp (nt 139 to 410)
2ad st-p
AGOAAGACTTCCGAGCGGTC - TGCCTTGGGGATAGGCTGAC
AGGAAGACTTCCGACOGCTC GAGCCATCCTGCCCACCCCA
Genotype
I 57bp cnt 148 to 204)
11 144bp (nt 148 to 291)
AGGAAGACTTCCGAGCCGTC CCAAGAGGGACCGGGAACCTC IHI 174bp (nt 148 to 321)
* Corresponding author. Mailing address: Dipartimento di Biome-
dicina, Universita di Pisa, Via San Zeno 37, I-56127 Pisa, Italy.
Phone: 39 50 553562. Fax: 39 50 555477.
IV 123bp (nt 148 to 270)
FIG. 1. Primers used for universal and genotype-specific PCR
analyses. nt, nucleotides; 5'-UTR, 5'-untranslated region.
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FIG. 2. Representative results of the genotype-specific PCR.
Lanes: A to D, single infections with genotype I (57 bp), II (144 bp),
III (174 bp), or IV (123 bp), respectively; E, infection with an
unclassified genotype; F to H, double infections with genotypes I
and II, I and III, or III and IV, respectively; I and L, DNA
molecular size markers (123-bp ladder and Hinfl-digested pBR322,
respectively).
stained with ethidium bromide. The sizes of amplicons were
determined by comparison with appropriate molecular size
markers (100-bp ladder [Pharmacia Biotech Europe], 123-bp
ladder [GIBCO BRL], and HinfI-digested pBR322) (Fig. 2).
Each serum specimen was examined at least twice, and no
conflicting results were observed.
The results are summarized in Table 1. The great majority
of the HCV examined (98%) were typed by the procedure
used. Among the community-acquired infections, HCV geno-
type II was largely dominant (60%), followed by genotypes
IV (15%), III (11%), and I (3%). Thus, it would appear that
the prevalence of HCV genotypes in Italy is similar to that
reported for Japan (8) and differs substantially from the
distribution observed in the United States (3, 12).
For the hemophilia-associated cases, the distribution of
the four HCV genotypes was markedly different: genotype I
was the most prevalent (61%), followed by genotypes II
(25%), III (4%), and IV (2%). This result most likely reflects
the fact that the concentrates used by these patients were
largely prepared from blood purchased abroad (9). Alterna-
tive explanations should, however, be considered. These
include the possibility that different HCV genotypes prefer-
entially use different means of transmission or react differ-
ently to the treatments used for the preparation of concen-
trates. Fifteen hemophiliacs were also infected with human
immunodeficiency virus type 1. No differences were noted in
the distribution of HCV genotypes in these patients com-
TABLE 1. HCV genotypes in Italian patients with community-
acquired or hemophilia-associated hepatitis C
No. of No. of patients with the following
Type of hepatitis patients HCV genotype:
examined I II III IV Mixed Unclassified
Community acquired 65 2a 39a 7 10 5b 2
Hemophilia associated 45 28 11 2 1 3c
a Significantly different from the hemophilia-associated group (chi-square
test; P < 0.001).
b Genotypes I and II, I and III, and III and IV in one patient each and II and
III in two patients.
c Genotypes I and II, I and IV, and III and IV in one patient each.
TABLE 2. HCV genotypes in Italian patients with community-
acquired hepatitis C, grouped according to results of liver biopsies
No. of No. of patients with the foliowingResult of liver patients HCV genotype:biopsy examned I II III IV Mixed
Persistent chronic 12 2 3a 2 4 lb
hepatitis
Active chronic 25 17 2 3 3c
hepatitis
Cirrhosis 8 7 1
aSignificantly different from the groups of patients with severe infections
(active chronic hepatitis and cirrhosis) (chi-square test; P < 0.01).
b Genotypes I and III.
c Genotypes II and III in two patients and genotypes III and IV in one
patient.
pared with the human immunodeficiency virus-seronegative
ones (data not shown). The concomitant presence of two
viral genotypes was observed in three hemophiliacs as well
as in five community-acquired cases.
A liver biopsy was available for 45 patients with commu-
nity-acquired hepatitis. As shown in Table 2, patients with
more severe degrees of liver damage (active chronic hepati-
tis or cirrhosis) showed a significantly higher prevalence of
genotype II than patients with persistent chronic hepatitis.
Although the numbers of patients examined are still too low
to draw firm conclusions on this important matter, these data
and other reports encourage further studies to better evalu-
ate the pathogenic potential of the various HCV genotypes
(1, 7, 13).
The two HCV which remained unclassified by the proce-
dure described above were not amplified, even when exam-
ined by use of the four genotype-specific primers separately.
The fact that under identical conditions of reaction such
viruses were consistently amplified by the universal primers
seems to exclude the possibility that the failure of typing was
due to the presence of inhibitors in the sera or to degradation
of the viral genome and suggests that they belong to geno-
types not covered by the primers used. Sequencing the core
region of these HCV might lead to the recognition of
additional, hitherto-unrecognized HCV genotypes.
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